Floatz logo

Jnj-54135419

Chronic Rhinosinusitis

The Second People's Hospital of Huai'anSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Chronic Rhinosinusitis cohort.

Asset / SponsorPhaseRating
Escitalopram
University of Washington
Phase 4BB
Omalizumab
University of California, San Francisco
Phase 4BB
METHOXIFLURANE
St. Paul's Hospital, Canada
Phase 1/2CCC
LAVENDER OIL
Cedars-Sinai Medical Center
N/AD
Ivacaftor
University of California, Los Angeles
UnknownD

View all 9 →

Same molecule, other indications

Jnj-54135419 is also rated in:

depressive disorderActive
BBB
Indicative · Phase 4
75 / 100
View asset →
chronic pain syndromeActive
BBB
Indicative · Phase 4
73 / 100
View asset →
major depressive disorderActive
BBB
Indicative · Phase 4
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →